Entrada Therapeutics (TRDA) Research & Development (2020 - 2026)

Entrada Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $33.1 million for Q1 2026.

• In Q1 2026, Research & Development rose 3.06% year-over-year to $33.1 million; the TTM figure through Mar 2026 stood at $143.2 million (up 11.24% YoY), while the FY2025 annual figure was $142.3 million, up 13.54% from the prior year.
• Research & Development was $33.1 million for Q1 2026 at Entrada Therapeutics, down from $34.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $38.4 million in Q3 2025 to a low of $15.7 million in Q4 2022.
• Historically, Research & Development has averaged $27.5 million across 5 years, with a median of $28.6 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Research & Development surged 152.58% in 2022, then rose 1.65% in 2025.
• A 5-year view of Research & Development shows it stood at $15.7 million in 2022, then jumped by 80.37% to $28.3 million in 2023, then grew by 18.08% to $33.4 million in 2024, then climbed by 1.65% to $34.0 million in 2025, then declined by 2.66% to $33.1 million in 2026.
• The last three Research & Development figures came in at $33.1 million (Q1 2026), $34.0 million (Q4 2025), and $38.4 million (Q3 2025), per Business Quant data.